Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk

Stock Information for Corvus Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.